Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 2/20 | 0.44 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.44 |
| ▸ | ITGB7 | P26010 | 2/20 | 0.44 |
| ▸ | SENP1 | Q9P0U3 | 2/20 | 0.42 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | KDM6A | O15550 | 1/20 | 0.39 |
| ▸ | KDM4A | O75164 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KDM5C | P41229 | 1/20 | 0.39 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.39 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.39 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.36 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.36 |
| ▸ | MAT2A | P31153 | 1/20 | 0.36 |
| ▸ | USP7 | Q93009 | 2/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18136496 | 0.81 | BRD4 (0.49) | ITGB1ITGA4ITGB7KDM4CKDM4E | |
| SCHEMBL9505269 | 0.72 | KDM4E (0.52) | KDM4EKDM6AKDM4ACYP2C9CYP2C19 | |
| SCHEMBL24195785 | 0.72 | LCK (0.40) | ITGB1ITGA4ITGB7BRD4MAP4K1 | |
| SCHEMBL29348991 | 0.71 | ITGB1 (0.38) | ITGB1ITGA4ITGB7HSD11B1 | |
| SCHEMBL29929295 | 0.71 | SENP1 (0.61) | SENP1KDM4EUSP7PREPCELA1 | |
| SCHEMBL4367504 | 0.71 | SENP1 (0.61) | SENP1KDM4EUSP7PREPCELA1 | |
| SCHEMBL12987761 | 0.69 | HRH3 (0.43) | ITGB1ITGA4ITGB7KDM4CKDM4E | |
| SCHEMBL6705151 | 0.69 | SENP1 (0.71) | SENP1KDM4EUSP7PREPCELA1 | |
| SCHEMBL24112194 | 0.69 | ATAD2 (0.40) | KDM4EKDM6AKDM4ACYP2C9CYP2C19 | |
| SCHEMBL4649779 | 0.68 | BRD4 (0.42) | ITGB1ITGA4ITGB7KDM4EKDM6A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250205219-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS AG (CH) | 2025-06-26 | — | — | US | disclosed |
| WO-2024151547-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250205219-A1 | TARGETED DEGRADATION OF VAV1 | VAV1, KRAS, CBL | ITGB1 1829/4885ITGA4 2704/4885ITGB7 2006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.